Currently out of the existing stock ratings of Matthew Caufield, 86 are a BUY (86.87%), 13 are a HOLD (13.13%).

Matthew Caufield

Work Performance Price Targets & Ratings Chart

Analyst Matthew Caufield, carries an average stock price target met ratio of 22.14% that have a potential upside of 65.7% achieved within 45 days. Previously, Matthew Caufield worked at HC WAINWRIGHT.

Matthew Caufield’s has documented 187 price targets and ratings displayed on 14 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on DMAC, DiaMedica Therapeutics at 29-May-2025.

Wall Street Analyst Matthew Caufield

Analyst best performing recommendations are on LYRA (LYRA THERAPEUTICS ).
The best stock recommendation documented was for LYRA (LYRA THERAPEUTICS ) at 3/14/2025. The price target of $2 was fulfilled within 75 days with a profit of $1.83 (1076.47%) receiving and performance score of 143.53.

Average potential price target upside

of $11.6 (68.02%) on ISEE (IVERIC BIO).
of $1.71 (726.33%) on LYRA (LYRA THERAPEUTICS ).
of $2.53 (45.75%) on KOD (KODIAK SCIENCES).

ALDX Aldeyra The EYEN Eyenovia FDMT 4D Molecular Therapeutics ISEE IVERIC bio OCUP Ocuphire Pharma OPT Opthea Ltd LYRA Lyra Therapeutics UBX Unity Biotechnology GMTX Gemini Therapeutics ADVM Adverum Biotechnologies DMAC DiaMedica Therapeutics KOD Kodiak Sciences OPTN OptiNose PHAT Phathom Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Matthew Caufield (HC WAINWRIGHT)